Comparing the current results to its competitors, Lantheus Holdings Inc reported Revenue increase in the 1 quarter 2026 by 1.13 % year on year. The revenue growth was below Lantheus Holdings Inc 's competitors' average revenue growth of 21.46 %, achieved in the same quarter.
Lantheus Holdings Inc 's Comment on Competition and Industry Peers
The company faces competition in the market expansion, penetration, and reimbursement of its commercial products, including PYLARIFY, DEFINITY, and Neuraceq. This competitive environment affects their ability to clinically and commercially differentiate these products. The company is also pursuing FDA approval for a new formulation of its F-18 PSMA PET imaging agent, completing technology transfer across its PET manufacturing facilities, securing FDA approval for each facility to manufacture the new formulation, and obtaining appropriate coding, coverage, and payment, including transitional pass-through payment status for the new formulation.
September 6, 2025
In an unfolding situation that has caught the attention of the investment community, Lantheus Holdings, Inc. (NASDAQ: LNTH) finds itself under the investigative lens of the Pomerantz Law Firm. The firm is probing claims on behalf of investors who may have been adversely affected by the company’s recent performance, which has raised eyebrows in light of contrasting results from its competitors. Declining Revenue Amidst Industry Growth In the second quarter of 2025, Lantheus reported a notable year-on-year revenue decrease of 4%. This decline is particularly alarming considering the broader landscape, where most of its competitors experienced a robust revenue increase averaging 12.26% during the same period...
June 3, 2024
Harnessing AI to Transform Diagnostic Imaging: A New Frontier in Prostate Cancer Detection By At the confluence of artificial intelligence and medical imaging, a significant breakthrough is making waves in the realm of prostate cancer detection. Lantheus Holdings, a pioneer in diagnostic medical imaging solutions, recently announced the integration of its advanced AI-enabled aPROMISE software onto the Siemens Healthineers syngo.via platform a move expected to substantially elevate the diagnostic capabilities of healthcare professionals. This integration will be prominently showcased at the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting.The aPROMISE (Automated Prostate Can...
January 9, 2024
As the medical technology industry experiences significant changes in cancer treatments, enterprises have started to acknowledge the potential of strategic collaborations to boost radiopharmaceutical oncology pipelines. A reflection of this evolving trend emanates from the recent partnership between Lantheus Holdings Inc., a leader in diagnostic imaging and nuclear medicine, and Perspective Therapeutics, a pioneer in targeting rare and hard-to-treat cancers.Lantheus has recently announced its strategic agreements with Perspective Therapeutics centered on an option to license the Pb212-VMTNET asset - a cutting-edge radiopharmaceutical apt for expanding oncology pipelines. Designed to target and fight rare neu...
Actinium Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of targeted therapies for the treatment of various cancers.
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
GE Healthcare Technologies Inc's business model is focused on providing innovative medical devices, healthcare information technology, and healthcare services to improve patient care and outcomes. The company offers a wide range of products and solutions in areas such as medical imaging, patient monitoring, diagnostics, and healthcare IT. They also collaborate with healthcare providers and partners to offer integrated solutions and support throughout the entire healthcare ecosystem.
Eli Lilly and Company operates as a global pharmaceutical firm that focuses on developing innovative medicines in areas such as diabetes, oncology, and neurodegeneration. Their business model emphasizes research and development, strategic partnerships, and a strong commitment to improving patient outcomes through advanced therapeutics.
Monopar Therapeutics Inc operates under a business model focused on developing and commercializing innovative therapeutics for the treatment of various cancers. The company aims to leverage strategic partnerships with academic institutions and other pharmaceutical companies to facilitate the development and distribution of their products.
Sources:
Lantheus Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Lantheus Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
